UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 25, 2013
 
PURE BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
 
         
Delaware
 
001-14468
 
33-0530289
(State or other jurisdiction of incorporation)
 
(Commission   File Number)
 
(IRS Employer Identification No.)
   
1725 Gillespie Way
El Cajon, California
 
92020
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (619) 596-8600
 
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 
 
 

Item 1.01. Entry into a Material Definitive Agreement.

On January 25, 2013, Pure Bioscience, Inc. (the “ Company ”) entered into a Letter Agreement (the “ Agreement ”) with Morrison & Foerster LLP (“ Morrison ”).  Under the terms of the Agreement, the Company issued a Promissory Note (the “ Note ”) in favor of Morrison  in the principal amount of $1,125,000.  In consideration for the Note, Morrison agreed to waive $1,518,540.55 of amounts due and payable to Morrison for legal services rendered.  The Note bears interest at the rate of 7.5% per annum, but the then outstanding balance will accrue interest at the rate of 10% per annum upon the occurrence of an event of default (as defined in the Note).  Beginning March 31, 2013, and on or before the last business day of each calendar month thereafter, the Company is required to pay all accrued but unpaid interest on the then unpaid amount of outstanding principal.  Beginning on February 28, 2014, the Company is required to pay equal monthly principal installments of $46,875.  The Company may prepay the outstanding balance under the Note in full or in part at any time, which prepayment will result in a discount of the then outstanding balance as more fully described in the Note.   The Note will mature on February 28, 2016, unless accelerated pursuant to an event of default (as defined in the Note) or upon the consummation of a change of control (as defined in the Note).  As a result of the Agreement, the Company will reclassify the amount due and payable to Morrison from a current liability to long-term debt on the Company’s balance sheet.

In consideration for Morrison’s acceptance of the Note in lieu of payment for its legal services, the Company issued Morrison a warrant to purchase 375,000 shares of the Company’s common stock at an exercise price of $0.83 per share.  The warrant is exercisable immediately and expires on January 24, 2018.  The warrant may be exercised by Morrison with a cash payment or, in lieu thereof, at its election, through a net exercise, as set forth in the warrant. Neither the warrant nor the shares to be issued upon exercise thereof are registered for sale or resale under the Securities Act of 1933, as amended (the “ Securities Act ”), and have been or will be issued in reliance on an exemption from registration under the Securities Act pursuant to Section 4(2) thereof based on the offering of such securities to one investor and the lack of any general solicitation or advertising in connection with such issuance.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

4.1 
Warrant, dated as of January 25, 2013, issued by Pure Bioscience, Inc. to Morrison & Foerster LLP
10.1 
Letter Agreement, dated as of January 25, 2013, between Pure Bioscience, Inc., and Morrison & Foerster LLP
10.2 
Promissory Note, dated as of January 25, 2013, in favor of Morrison & Foerster LLP


 
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
PURE BIOSCIENCE, INC.
   
   
Dated: January 31, 2013
By:      /s/ Michael L. Krall
 
          Michael L. Krall
 
          President, Chief Executive Officer
 
          (Principal Executive Officer)
   
   


 
 
 
EXHIBIT INDEX
 
 
Exhibit
Number
Description
 
4.1 
Warrant, dated as of January 25, 2013, issued by Pure Bioscience, Inc. to Morrison & Foerster LLP
10.1 
Letter Agreement, dated as of January 25, 2013, between Pure Bioscience, Inc., and Morrison & Foerster LLP
10.2 
Promissory Note, dated as of January 25, 2013, in favor of Morrison & Foerster LLP




Exhibit  4.1
 
 

 
NEITHER THIS WARRANT NOR THE UNDERLYING SHARES OF COMMON STOCK HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS.  NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 5 OF THIS WARRANT.
 
PURE BIOSCIENCE, INC.
 
WARRANT TO PURCHASE 375,000 SHARES
OF COMMON STOCK
 
THIS CERTIFIES THAT, for value received, Morrison & Foerster LLP (“ Holder ”) is entitled, at any time on or after January 25, 2013 (the “ Date of Grant ”) and on or prior to the close of business on January 24, 2018 but not thereafter, to subscribe for and purchase up to 375,000 shares of the fully paid and nonassessable Common Stock (as adjusted pursuant to Section 2 hereof, the “ Shares ”) of PURE Bioscience, Inc., a Delaware corporation (the “ Company ”), at the price of $ 0.83 per share (such price and such other price as shall result, from time to time, from the adjustments specified in Section 2 hereof is herein referred to as the “ Warrant Price ”), subject to the provisions and upon the terms and conditions hereinafter set forth.  As used herein, the term “ Common Stock ” shall mean the Company’s Common Stock, $0.01 par value,  or any stock into or for which such Common Stock may hereafter be converted or exchanged prior to or concurrent with the exercise of this Warrant.
 
This Warrant is issued to Holder by the Company pursuant to a letter agreement between the Company and the Holder dated January 25, 2013.
 
1.   Exercise of Warrant .
 
(a)   Method of Exercise; Payment . The purchase right represented by this Warrant may be exercised by the Holder, in whole or in part and from time to time, at the election of Holder, by (a) the surrender of this Warrant (with the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the principal office of the Company and by the payment to the Company, by certified or bank check, or by wire transfer to an account designated by the Company of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased, or (b) exercise of the “net issuance” right provided for in Section 1(b) hereof.  The person or persons in whose name(s) any certificate(s) representing the Shares shall be issuable upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the Shares represented thereby (and such Shares shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which this Warrant is exercised.  In the event of any exercise of the rights represented by this Warrant, certificates for the Shares so purchased shall be delivered to Holder as soon as practicable and, if requested by Holder, the Company shall cause its transfer agent to deliver the certificate representing Shares issued upon exercise of this Warrant to a broker or other person (as directed by Holder) within the time period required to settle any trade made by Holder after exercise of this Warrant.
 
 
1
 
(b)   Right to Convert Warrant into Stock; Net Issuance .
 
(i)   Right to Convert .  In addition to and without limiting the rights of Holder under the terms of this Warrant, Holder shall have the right to convert this Warrant or any portion thereof (the “ Conversion Right ”) into Shares of Common Stock as provided in this Section 1(b) .  Upon exercise of the Conversion Right with respect to a particular number of Shares (the “ Converted Warrant Shares ”), the Company shall deliver to Holder (without payment by Holder of any exercise price or any cash or other consideration) that number of Shares as is determined according to the following formula:
 
   X =   B - A     
    Y    
 
  Where:  X  =
the number of Shares that may  be issued to the holder
 
     Y  =
the fair market value of one share of Common Stock
 
     A  =
the aggregate Warrant Price of the specified number  of Converted Warrant Shares immediately prior to the exercise of the Conversion Right ( i.e., the number of Converted Warrant Shares multiplied by the Warrant Price)
 
     B  =
the aggregate fair market value of the specified  number of converted Warrant Shares ( i.e. , the number of Converted Warrant Shares multiplied by the fair  market value of one Converted Warrant Shares)
 
No fractional shares shall be issuable upon exercise of the Conversion Right, and, if the number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, then the number of Shares issued upon exercise of the Conversion Right shall be rounded down to the nearest whole number.
 
(ii)   Method of Exercise .  The Conversion Right may be exercised by Holder by the surrender of this Warrant at the principal office of the Company together with a written statement in the form of Exhibit A-2 hereto specifying that Holder thereby intends to exercise the Conversion Right and indicating the number of Shares which are being surrendered (referred to in Section 1(b)(i) hereof as the Converted Warrant Shares) in exercise of the Conversion Right.  The effective date of such conversion is referred to herein as the “ Conversion Date ”.  Certificates for the Shares issuable upon exercise of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the Holder as soon as practicable, but in no event later than 10 days following the Conversion Date.
 
 
2
 
(iii)   Determination of Fair Market Value .  For purposes of this Section 1(b), “ fair market value ” of a share of Common Stock as of a particular date shall mean:
 
(1)   The average of the closing sales prices of the Common Stock quoted on the Nasdaq Stock Market or any other exchange on which the Common Stock is listed, whichever is applicable, for the ten trading days prior to the date of determination of fair market value; or
 
(2)   If the Common Stock is not traded on the Nasdaq Stock Market or any other exchange, fair market value of the Common Stock per share shall be determined in good faith by the Company’s Board of Directors.
 
2.   Adjustment of Warrant Price and Number of Shares .  The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows:
 
(a)   Subdivision or Combination of Shares .  If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine its outstanding shares of Common Stock, the Warrant Price shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision or and the Warrant Price shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in the case of a combination.
 
(b)   Stock Dividends .  If the Company at any time while this Warrant is outstanding and unexpired shall pay a dividend with respect to its Common Stock payable in Common Stock, then the Warrant Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution.
 
(c)   Adjustment of Number of Shares .  Upon each adjustment in the Warrant Price, the number of Shares purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter.
 
 
3
 
(d)   Consolidation, Merger or Sale of Assets .   In case of any consolidation of the Company with, or merger of the Company with or into any other entity (other than a merger which does not result in any reclassification, conversion, exchange or cancellation of outstanding shares of Stock), or any sale or transfer of all or substantially all of the assets of the Company or of the person formed by such consolidation or resulting from such merger or which acquires such assets, as the case may be, the Holder shall have the right thereafter to exercise this Warrant for the kind and amount of securities, cash and other property receivable upon such consolidation, merger, sale or transfer by a holder of the number of shares of Stock for which this Warrant may have been exercised immediately prior to such consolidation, merger, sale or transfer.  Adjustments for events subsequent to the effective date of such a consolidation, merger and sale of assets shall be as nearly equivalent as may be practicable to the adjustments provided for in Section 2 hereof.  In any such event, effective provisions shall be made in the certificate or articles of incorporation of the resulting or surviving corporation, in any contract of sale, conveyance, lease or transfer, or otherwise so that the provisions set forth herein for the protection of the rights of the Holder shall thereafter continue to be applicable; and any such resulting or surviving corporation shall expressly assume the obligation to deliver, upon exercise, such shares of stock, other securities, cash and property.  The provisions of this Section 2(d) shall similarly apply to successive consolidations, mergers, sales, leases or transfers.
 
3.   Notice of Certain Events .  Whenever the Warrant Price or the number of Shares purchasable hereunder shall be adjusted pursuant to Section 2 hereof, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of such certificate to be mailed to the holder of this Warrant at such holder’s last known address.
 
4.   Fractional Shares .  No fractional shares of Common Stock will be issued in connection with any exercise hereunder.
 
5.   Compliance with Securities Act; Disposition of Warrant or Shares of Common Stock .
 
(a)   Representations of Holder .  The Holder, by acceptance hereof, agrees that this Warrant and the Shares to be issued upon exercise hereof are being acquired for investment and that Holder will not offer, sell or otherwise dispose of this Warrant or any Shares except under circumstances which will not result in a violation of the Securities Act of 1933, as amended (the “ Securities Act ”) or any applicable state securities laws. In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of this Warrant as follows:
 
(i)   Holder is aware of the Company’s business affairs and financial condition, and has acquired information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant.  Holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution” thereof in violation of the Securities Act.
 
 
4
 
(ii)   Holder understands that this Warrant has not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Holder’s investment intent as expressed herein.
 
(iii)   Holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Securities Act and qualified under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available.  Holder is aware of the provisions of Rule 144, promulgated under the Securities Act.
 
(iv)   Holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act.
 
(v)   Holder has the requisite power and authority to execute and deliver this Warrant and to perform its obligations hereunder.
 
(b)   Transfer. This Warrant or the Shares may be offered, sold or otherwise disposed of in accordance with Rule 144 under the Securities Act, provided that the Company shall have been furnished with such information as the Company may reasonably request to provide a reasonable assurance that the provisions of Rule 144 have been satisfied.  Each certificate representing this Warrant or the Shares thus transferred (except a transfer pursuant to Rule 144) shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the opinion of counsel for the holder, such legend is not required in order to ensure compliance with such laws.
 
6.   Rights as Stockholders; Information .  No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed the holder of Common Stock or any other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.
 
7.   Representations and Warranties of the Company .  The Company represents and warrants to Holder as follows:
 
(a)   This Warrant has been duly authorized and executed by the Company and is a valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies;
 
 
5
 
(b)   The Shares have been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof will be validly issued, fully paid and non-assessable; and
 
(c)   The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with the terms hereof will not be, in conflict with the Company’s certificate of incorporation or bylaws.
 
8.     Modification and Waiver .  This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought.
 
9.   Notices .  Any notice, request, communication or other document required or permitted to be given or delivered to the holder hereof or the Company shall be delivered, or shall be sent by reputable overnight courier service, certified or registered mail, postage prepaid with return receipt requested, to the initial holder at the address set forth below, to any subsequent holder at its address as shown on the books of the Company or to the Company at the address set forth below.
 
If to the holder:
 
Chief Financial Officer
Morrison & Foerster LLP
555 Market Street
San Francisco, CA 94105
Tel. No.: (415) 268-7000
Fax No.: (415) 268-7522

 
If to the Company:

PURE Bioscience, Inc.
Attn:  Chief Executive Officer
1725 Gillespie Way
El Cajon, CA  92020
Tel. No.: (619) 596-8600
Fax No.: (619) 596-8700

 
Each of the foregoing parties shall be entitled to specify a different address by giving five days’ advance written notice as aforesaid to the other parties.  All such notices and communications shall be deemed to have been received (a) upon hand delivery by telecopy or facsimile at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the first business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.
 
 
6
 
10.   Binding Effect on Successors .  This Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets.
 
11.   Lost Warrants or Stock Certificates .  The Company covenants to Holder that, upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate.
 
12.   Descriptive Headings .  The descriptive headings of the several paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant.  The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted this Warrant.
 
13.   Governing Law .  This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of California.
 
14.   Survival of Representations, Warranties and Agreements .  All representations and warranties of the Company and Holder contained herein shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration of rights hereunder.  All agreements of the Company and the holder hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer operative.
 
15.   Remedies .  In case any one or more of the covenants and agreements contained in this Warrant shall have been breached, Holders (in the case of a breach by the Company), or the Company (in the case of a breach by Holder), may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant.
 
16.   No Impairment of Rights .  The Company will not, by amendment of its charter documents or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against impairment.
 
17.   Severability .  The invalidity or unenforceability of any provision of this Warrant in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and effect.
 
 
7
 
18.   Entire Agreement; Modification .  This Warrant constitutes the entire agreement between the parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written, with respect to such subject matter.
 
  PURE BIOSCIENCE, INC.  
       
 
By:
/s/ Michael Krall  
  Title: President and CEO  
       
       

                                                                           
 
8
 


 
EXHIBIT A-1
 
NOTICE OF EXERCISE
 
To:  PURE Bioscience, Inc. (the “Company”)
 
1.           The undersigned hereby elects to purchase     ____________ shares of Common Stock of the Company pursuant to the terms of the attached Warrant.
 
2.           The undersigned elects to exercise the attached Warrant by means of a cash payment and tenders herewith payment of the purchase price of such shares in full. The undersigned represents that the aforesaid shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable securities laws.  The undersigned represents that it is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended.
 
3.           Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name or names as are specified below:
                                                                           
 
 
(Name)
 
 
 
 
(Address)
                                                                           
 
                                                   
 
 
Name of Holder
 
 
Signature of Authorized Signatory
 
 
Name and Title of Signatory
 
                        
 

 
Date:    _____________
                                       
 
1
 
 
EXHIBIT A-2
 
NOTICE OF NET EXERCISE
 
To:  PURE Bioscience, Inc. (the “Company”)
 
1.           The undersigned hereby elects to purchase ____________ shares of Common Stock of the Company pursuant to the terms of the attached Warrant.
 
2.           The undersigned elects to exercise the attached Warrant and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any, by means of a cashless exercise, such that payment shall take the form of the cancellation of such number of shares of Common Stock of the Company as is necessary, in accordance with the formula set forth in subsection 1(b), to exercise this Warrant with respect to the above number of shares of Common Stock purchasable pursuant to the cashless exercise procedure set forth in subsection 1(b).
 
3.           Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name or names as are specified below:
 

 
 
(Name)
 
 
 
 
(Address)
                                                                           
 
                                                   
 
 
Name of Holder
 
 
Signature of Authorized Signatory
 
 
Name and Title of Signatory
 
         
                  
Date:    _____________
 
 
2
 
Exhibit 10.1
 
 
 
    425 MARKET STREET
SAN FRANCISCO
CALIFORNIA  94105-2482
 
TELEPHONE: 415.268.7000
FACSIMILE: 415.268.7522
 
WWW.MOFO.COM
morrison & foerster llp
 
new york, san francisco,
los angeles, palo alto,
sacramento, san diego,
denver, northern virginia,
washington, d.c.
tokyo, london, brussels,
beijing, shanghai, hong kong
 
Writer’s Direct Contact
 
415.268.7999
PCavaney@mofo.com
 
 
January 25, 2013
 
Michael Krall
Chief Executive Officer
Pure Bioscience, Inc.
1725 Gillespie Way
El Cajon, CA 92020
 
Dear Mike:
 
This letter agreement (the “Agreement”) sets forth the agreement between Morrison & Foerster LLP (“Morrison”) and Pure Bioscience, Inc., a Delaware corporation (the “Company”) regarding amounts due and payable to Morrison for legal services rendered.
 
We have reviewed the letter dated September 11, 2012 from The Nasdaq Stock Market regarding the conditions to the Company’s continued listing on the Nasdaq Capital Market, and we understand that a reduction in the amounts payable to Morrison is a necessary part of the Company’s ability to satisfy the minimum forecasted stockholders’ equity requirement.
 
Based in part upon the foregoing, Morrison and the Company agree as follows:
 
1.  
In consideration for the issuance by the Company of the Promissory Note attached hereto as Exhibit A (the “Note”) in the principal amount of $1,125,000 Morrison will waive $1,518,540.55 of amounts payable for the invoices listed on Schedule 1 .
 
2.  
In consideration for Morrison’s acceptance of the Note in lieu of payment of the invoices listed on Schedule 1 , the Company will issue to Morrison a warrant to purchase 375,000 shares of the Company’s common stock at an exercise price of $0.83 per share in the form attached hereto as Exhibit E (the “Warrant”).
 
For the avoidance of doubt, the Company and Morrison acknowledge and agree that the issuance of the Notes and Warrant shall be in full satisfaction of the obligations under the invoices listed on Schedule 1 .  Morrison hereby releases any claim it has or may have to payment of such obligations.
 
 
 
 
 
The Company acknowledges and agrees (i) that the terms of this Agreement are fair and reasonable to the Company, (ii) that Morrison has advised the Company of all terms of the transaction in writing and the Company has obtained advice from independent counsel with respect to this Agreement, the Notes and the Warrant and (iii) that the Company consents to the terms of this Agreement and the actions contemplated hereby.
 
This Agreement does not, modify the terms of our engagement letter with you dated April 17, 2007, except as specifically provided herein.
 
To indicate the Company’s agreement to the foregoing, please sign in the space provided below.  Please return a copy to Scott Stanton by facsimile (858) 523-5941 or electronically to SStanton@mofo.com .
 
Sincerely,
 
 
/s/ Pat Cavaney
Pat Cavaney
Chief Operating Officer
 

Agreed and Acknowledged:

PURE BIOSCIENCE, INC.


By:       /s/ Michael Krall
Michael Krall, Chief Executive Officer


Dated:   January 25, 2013
 
           
 
 
 

Schedule 1

Invoices Exchanged for Promissory Notes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 10.2
 
 
PROMISSORY NOTE
 
U.S. $1,125,000   Issuance Date:   January 25, 2013
                                                                                                                                          
FOR VALUE RECEIVED , the undersigned PURE BIOSCIENCE, INC. a Delaware corporation (“ Maker ”), hereby promises to pay to the order of MORRISON & FOERSTER LLP (“ Payee ”) at 425 Market Street, San Francisco, CA , 94105, or at such other place or to such other party as Payee may from time to time designate, the principal sum of ONE MILLION ONE HUNDRED TWENTY FIVE THOUSAND DOLLARS AND ZERO CENTS ($1,125,000.00), plus interest from the date hereof, in lawful money of the United States of America and in immediately available funds on the terms and subject to the conditions set forth below. This Note is issued by Maker to Payee in full satisfaction of certain invoices for services rendered by Payee on behalf of Maker through December 31, 2012.
 
1.   Maturity Date .  Unless sooner paid in accordance with the terms hereof, the entire unpaid principal amount and all accrued interest shall become fully due and payable on the earliest of (i) February 28, 2016, (ii) the consummation of a Change of Control (as defined below) or (iii) the acceleration of the maturity of this Note by the Payee upon the occurrence and during the continuance of an Event of Default (such earlier date, the “ Maturity Date ”).  The entire amount of unpaid principal and accrued but unpaid interest, if any, shall be due and payable on the Maturity Date. For purposes of this Note, “ Change of Control ” shall mean (A) the acquisition of Maker by another entity by means of any reorganization, merger or consolidation (but excluding any reorganization, merger or consolidation effected exclusively for the purpose of changing the domicile of Maker), (B) any transaction or series of related transactions in which Maker’s shareholders of record as constituted immediately prior to such transaction or series of related transactions will, immediately after such transaction or series of related transactions (by virtue of securities issued in such transaction or series of related transactions) fail to hold at least 50% of the voting power of the resulting or surviving corporation following such transaction or series of related transactions, or (C) a sale of all or substantially all of the assets of Maker by means of a transaction or series of related transactions.
 
2.   Interest .  Interest on the outstanding balance of this Note shall be computed from the Issuance Date at the per annum rate of seven and one-half percent (7.5%) (computed on the basis of actual calendar days elapsed and a year of 365 days) or, if less, at the highest rate of interest then permitted under applicable law, and shall continue to accrue until paid in full; provided, however, upon the occurrence of an Event of Default (as defined in Section 5 below), the outstanding balance of this Note shall accrue interest at the per annum rate of ten percent (10%) (computed on the basis of actual calendar days elapsed and a year of 365 days) or, if less, at the highest rate permitted under applicable law, and shall continue to accrue until paid in full.  Accrued unpaid interest shall be due and payable at the times and at the interest rate as set forth herein until all principal and accrued interest owing on this Note shall have been fully paid and satisfied.
 
 
1
 
3.   Payment .
 
(a)            Form of Payment .  All payments of interest and principal shall be in lawful money of the United States of America to Payee by wire transfer.  All payments shall be applied first to accrued interest, and thereafter to principal.
 
(b)            Principal and Interest Payments .  Beginning on March 31, 2013, and on or before the last business day of each calendar month thereafter, Maker shall pay Payee all accrued but unpaid interest on the then unpaid amount of outstanding principal.  In addition, beginning on February 28, 2014, and on or before the last business day of each calendar month thereafter, Maker shall pay Payee equal principal installments of $46,875. If any amount of principal or interest remains unpaid as of January 31, 2016, such remaining amount shall be paid in full by the Maturity Date.
 
4.   Prepayment .  Maker reserves the right to prepay the outstanding balance under this Note in full or in part at any time during the term of this Note without notice and without premium or penalty.  If Maker prepays the entire amount of unpaid principal and accrued but unpaid interest prior to June 30, 2013, the balance of principal outstanding at the time of such prepayment shall be reduced by thirty-three percent (33%).  If Maker prepays the entire amount of unpaid principal and accrued but unpaid interest after June 30, 2013 but prior to September 30, 2013, the balance of principal outstanding at the time of such prepayment shall be reduced by twenty percent (20%).  If Maker prepays the entire amount of unpaid principal and accrued but unpaid interest after September 30, 2013 but prior to December 15, 2013, the balance of principal outstanding at the time of such prepayment shall be reduced by ten percent (10%).
 
5.   Events of Default; Remedies .  Any one of the following occurrences shall constitute an “ Event of Default ” under this Note:
 
(a)   Maker fails to make a payment of any installment of principal or interest on this Note when and as the same becomes due and payable in accordance with the terms hereof, whether upon the Maturity Date or upon any date upon which a monthly payment is due or by acceleration or otherwise;
 
(b)   Maker fails to perform any obligation under this Note;
 
(c)   Maker or any of its Subsidiaries shall (i) liquidate, wind up or dissolve (or suffer any liquidation, wind-up or dissolution), (ii) suspend its operations other than in the ordinary course of business or (iii) take any action to authorize any of the actions or events set forth above in this Section 5(d);
 
(d)   Any judgments or arbitration awards shall be entered against Maker or any of its Subsidiaries, or Maker or any of its Subsidiaries shall enter into any settlement agreements with respect to any litigation or arbitration, in the amount of One Hundred Thousand Dollars ($100,000) or more, and such judgment, award or agreement has not been satisfied, vacated, discharged or stayed or bonded pending appeal within thirty (30) days after the entry thereof; or Maker or any of its subsidiaries shall be enjoined, restrained or in any way prevented by court order from continuing to conduct all or any material part of its business affairs;
 
 
2
 
(e)   Maker becomes insolvent or bankrupt, commits any act of bankruptcy, generally fails to pay its debts as they become due, becomes the subject of any proceedings or action of any regulatory agency or any court relating to insolvency, or makes an assignment for the benefit of its creditors, or enters into any agreement for the composition, extension, or readjustment of all or substantially all of his obligations;
 
(f)   The holder of any indebtedness of Maker accelerates any payment of any amount or amounts of principal or interest on any such indebtedness (the “ Indebtedness ”) (other than with respect to this Note) prior to its stated maturity or payment date, the aggregate principal amount of which Indebtedness is in excess of $100,000, whether such Indebtedness now exists or shall hereinafter be created, and such accelerated payment entitles the holder thereof to immediate payment of such Indebtedness which is due and owing and such indebtedness has not been discharged in full or such acceleration has not been stayed, rescinded or annulled within fifteen (15) business days of such acceleration.
 
6.   Consequences of Events of Default .  Upon the occurrence of any Event of Default hereunder, Payee shall send a written notice of such default to Maker declaring the nature of the Event of Default.  Maker shall have ten (10) business days to cure any Event of Default, if such Event of Default may be cured within such time.  If the Event of Default is not so cured, then Maker shall immediately (and in no event later than two (2) days thereafter) pay the entire outstanding balance under this Note to Payee.  Maker agrees to pay Payee all out-of-pocket costs and expenses incurred by Payee in an effort to collect indebtedness under this Note, including attorneys’ fees and to pay interest at the post-default interest rate as provided in Section 2 of this Note.
 
7.   Independent Counsel; Terms of Transaction .  Maker acknowledges and agrees (i) that the terms of this Note are fair and reasonable to Maker, (ii) that Payee has advised Maker of all terms of the transaction in writing and Maker has been urged to, and given the opportunity to, seek the advice of an independent counsel of Maker’s choice, (iii) that Maker has had a reasonable opportunity to seek such advice from such independent counsel and (iv) that Maker consents to the terms of this Note and the actions contemplated hereby.
 
8.   Miscellaneous .
 
(a)   Lost, Stolen, Destroyed or Mutilated Notes .  In case any Note shall be mutilated, lost, stolen or destroyed, Maker shall have received an executed lost note affidavit attesting to the same, Maker shall issue a new Note of like date, tenor and denomination and deliver the same in exchange and substitution for and upon surrender and cancellation of any mutilated Note, or in lieu of any Note lost, stolen or destroyed, upon receipt of evidence satisfactory to Maker of the loss, theft or destruction of such Note.
 
(b)   Amendment and Waiver .  Any term of this Note may be amended and the observance of any term of this Note may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of Maker and Payee.  Any amendment or waiver effected in accordance with this Section shall be binding upon Maker and Payee.
 
 
3
 
(c)   Notices .  Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing and shall be effective (a) upon hand delivery by telecopy or facsimile at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the first business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.
 
Address of Payee:
Chief Financial Officer
 
Morrison & Foerster LLP
 
555 Market Street
San Francisco, CA 94105
Tel. No.: (415) 268-7000
Fax No.: (415) 268-7522
 
Address of Maker: 
Pure Bioscience, Inc.
1725 Gillespie Way
El Cajon, CA 92020
Attention: Chief Executive Officer
Tel. No.: (619) 596-8600
Fax No.: (619) 596-8700
 

(d)   Severability .  If one or more provisions of this Note are held to be unenforceable under applicable law, such provision shall be excluded from this Note and the balance of the Note shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.
 
(e)   Remedies Cumulative; Failure or Indulgence Not a Waiver .  The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note.  No failure or delay on the part of Payee in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege.
 
(f)   Waiver .  Maker waives diligence, presentment, protest and demand and also notice of protest, demand, dishonor and nonpayment of this Note.  No extension of time for the payment of this Note shall affect the original liability under this Note of Maker.  The pleading of any statute of limitations as a defense to any demand against Maker is expressly waived by Maker to the full extent permitted by law.
 
(g)   Setoff .  The obligation to pay Payee shall be absolute and unconditional and the rights of Payee shall not be subject to any defense, setoff, counterclaim or recoupment or by reason of any indebtedness or liability at any time owing by Payee to Maker.
 
(h)   Governing Law .  This Note shall be governed by and construed in accordance with the laws of the State of California.
 
 
4
 
(i)   Successors and Assigns .  This Note shall inure to the benefit of Payee and its successors and assigns.  The obligations of Maker hereunder shall not be assignable.
 
(j)   Excessive Interest .  Notwithstanding any other provision herein to the contrary, this Note is hereby expressly limited so that the interest rate charged hereunder shall at no time exceed the maximum rate permitted by applicable law.  If, for any circumstance whatsoever, the interest rate charged exceeds the maximum rate permitted by applicable law, the interest rate shall be reduced to the maximum rate permitted, and if Payee shall have received an amount that would cause the interest rate charged to be in excess of the maximum rate permitted, such amount that would be excessive interest shall be applied to the reduction of the principal amount owing hereunder (without charge for prepayment) and not to the payment of interest, or if such excessive interest exceeds the unpaid balance of principal, such excess shall be refunded to Maker.
 
[ Signature page to follow ]
 
 
 
 
 
 
5
 
IN WITNESS WHEREOF, the undersigned has executed and delivered this Note as of the date first above written.
 
 
 
“MAKER”
 
PURE BIOSCIENCE, INC.,
a Delaware corporation
 
       
 
By:
/s/ Michael Krall  
   
Michael Krall, Chief Executive Officer
 
       
       
 
 
 

 
6